
Acurx Secures Regulatory and Trademark Approval for Ibezapolstat Brand
Acurx Pharmaceuticals has received conditional FDA acceptance and a federal trademark allowance from the USPTO for the name CIFBEZY. The branding marks a strategic step in the commercial development of ibezapolstat, the company's lead antibiotic candidate currently preparing for international Phase 3 clinical trials targeting Clostridioides difficile infection.
























